Atai Life Sciences Nv logo

Atai Life Sciences Nv Share Price (NASDAQ: ATAI)

$4.57

-0.08

(-1.72%)

Last updated on

Check the interactive Atai Life Sciences Nv Stock chart to analyse performance

Atai Life Sciences Nv stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$4.45
    Today's High:$4.72

    Day's Volatility :5.72%

  • 52 Weeks Low:$1.03
    52 Weeks High:$5.34

    52 Weeks Volatility :80.71%

Atai Life Sciences Nv Stock Returns

PeriodAtai Life Sciences NvSector (Health Care)Index (Russel 2000)
3 Months
83.53%
3.6%
0.0%
6 Months
204.67%
-7.7%
0.0%
1 Year
274.59%
-12.6%
0.0%
3 Years
4.1%
9.5%
-4.7%

Atai Life Sciences Nv Key Stats

Check Atai Life Sciences Nv key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$4.65
Open
$4.66
Today's High
$4.72
Today's Low
$4.45
Market Capitalization
$996.7M
Today's Volume
$3.1M
52 Week High
$5.34
52 Week Low
$1.03
Revenue TTM
$2.3M
EBITDA
$-94.8M
Earnings Per Share (EPS)
$-0.69
Profit Margin
0.0%
Quarterly Earnings Growth YOY
-0.97%
Return On Equity TTM
-76.5%

Stock Returns calculator for Atai Life Sciences Nv Stock including INR - Dollar returns

The Atai Life Sciences Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Atai Life Sciences Nv investment value today

Current value as on today

₹3,56,823

Returns

₹2,56,823

(+256.82%)

Returns from Atai Life Sciences Nv Stock

₹2,51,538 (+251.54%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Atai Life Sciences Nv Stock

-15.38%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Investment in Atai Life Sciences Nv Shares from India has dropped by -15.38% over the past 30 days, indicating reduced transactional activity.

-37%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Atai Life Sciences Nv Stock from India on INDmoney has decreased by -37% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Atai Life Sciences Nv

  • Name

    Holdings %

  • UBS Group AG

    2.61%

  • Morgan Stanley - Brokerage Accounts

    1.55%

  • Pale Fire Capital SE

    1.24%

  • Millennium Management LLC

    0.54%

  • Moore Capital Management, LP

    0.45%

  • Brown University

    0.34%

Analyst Recommendation on Atai Life Sciences Nv Stock

Rating
Trend

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 13 Wall street analysts offering stock ratings for Atai Life Sciences Nv(by analysts ranked 0 to 5 stars)

Atai Life Sciences Nv Share Price Target

What analysts predicted

Upside of 146.95%

Target:

$11.29

Current:

$4.57

Atai Life Sciences Nv share price target is $11.29, a slight Upside of 146.95% compared to current price of $4.57 as per analysts' prediction.

Atai Life Sciences Nv Stock Insights

  • Price Movement

    In the last 1 month, ATAI stock has moved up by 31.7%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 1.55M → 719.0K (in $), with an average decrease of 53.8% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -26.43M → -27.72M (in $), with an average decrease of 4.9% per quarter
  • ATAI vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 105.8%

Atai Life Sciences Nv Technicals Summary

Sell

Neutral

Buy

Atai Life Sciences Nv is currently in a neutral trading position according to technical analysis indicators.

Atai Life Sciences Nv Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Atai Life Sciences Nv logo
11.46%
204.67%
274.59%
4.1%
-76.5%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About Atai Life Sciences Nv

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Organization
Atai Life Sciences Nv
Employees
54
CEO
Dr. Srinivas G. Rao M.D., Ph.D.
Industry
Commercial Services

Key Management of Atai Life Sciences Nv

NameTitle
Mr. Christian Angermayer
Co-Founder & Chairman of the Supervisory Board
Dr. Srinivas G. Rao M.D., Ph.D.
Co-Founder, CEO & Executive Director
Ms. Anne Johnson
Chief Financial Officer
Dr. Gerd G. Kochendoerfer Ph.D.
Chief Operating Officer
Dr. Glenn Short Ph.D.
Chief Scientific Officer
Mr. Ryan Barrett J.D.
General Counsel & Corporate Secretary
Dr. Kevin Craig M.D.
Chief Medical Officer

Important FAQs about investing in ATAI Stock from India :

What is Atai Life Sciences Nv share price today?

Atai Life Sciences Nv share price today is $4.57 as on at the close of the market. Atai Life Sciences Nv share today touched a day high of $4.72 and a low of $4.45.

What is the 52 week high and 52 week low for Atai Life Sciences Nv share?

Atai Life Sciences Nv share touched a 52 week high of $5.34 and a 52 week low of $1.03. Atai Life Sciences Nv stock price today i.e. is closed at $4.57, lower by 14.42% versus the 52 week high.

How to invest in Atai Life Sciences Nv Stock (ATAI) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Atai Life Sciences Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Atai Life Sciences Nv Shares that will get you 0.3282 shares as per Atai Life Sciences Nv share price of $4.57 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Atai Life Sciences Nv Stock (ATAI) from India?

Indian investors can start investing in Atai Life Sciences Nv (ATAI) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Atai Life Sciences Nv stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Atai Life Sciences Nv share’s latest price of $4.57 as on August 30, 2025 at 1:29 am IST, you will get 2.1882 shares of Atai Life Sciences Nv. Learn more about fractional shares .

What are the returns that Atai Life Sciences Nv has given to Indian investors in the last 5 years?

Atai Life Sciences Nv stock has given -76.5% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?